[February 19, 2013]

Research and Markets: Regenerative medicine and Stem cells Partnering Terms and Agreements

Research and Markets (http://www.researchandmarkets.com/research/tb9cmt/regenerative) has announced the addition of the "Regenerative medicine and Stem cells Partnering Terms and Agreements" report to their offering.

The Regenerative Medicine and Stem Cells Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the Regenerative medicine and Stem cells partnering deals and agreements entered into by the worlds leading healthcare companies.

- Trends in regenerative medicine and stem cells deals

- Deal terms analysis

- Partnering agreement structure

- Partnering contract documents

- Top deals by value

- Most active dealmakers

- Average deal terms for regenerative medicine and stem cells

The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine and stem cells partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors regenerative medicine and stem cells technology. These dealstend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest regenerative medicine and stem cells agreements including cell therapy agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all regenerative medicine and stem cells partnering deals announced since 2008 including financial terms where available including over 550 links to online deal records as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in regenerative medicine and stem cells dealmaking

Chapter 3 - Leading regenerative medicine and stem cells deals

Chapter 4 - Bigpharma regenerative medicine and stem cells deals

Chapter 5 - Regenerative medicine and stem cells partnering contracts directory

Chapter 6 - Regenerative medicine and stem cells dealmaking by technology type

Companies Mentioned

- Abbott

- Astellas

- AstraZeneca

- Bayer

- Boehringer Ingelheim

- Bristol-Myers Squibb

- Eisai

- Eli Lilly

- GlaxoSmithKline

- Johnson & Johnson

- Kyowa Hakko Kirin

- Merck & Co

- Novartis

- Otsuka

- Pfizer

- Roche

- Sanofi

- Teva

- UCB

For more information visit http://www.researchandmarkets.com/research/tb9cmt/regenerative

[ Back To Technology News's Homepage ]